by susuguo | Feb 17, 2023
“Academic literature estimates the effect of future drug revenues on R&D spending and finds that, on average, a 1 percent reduction in revenue leads to a 1.5 percent reduction in R&D activity,” a 2021 paper from University of Chicago’s Tomas Philipson and Troy...
by susuguo | Jan 11, 2023
By Rob Arnott and Casey B. Mulligan Covid-19 is deadly, but so were the draconian steps taken to mitigate it. During the first two years of the pandemic, “excess deaths”—the death toll above the historical trend—markedly exceeded the number of deaths attributed to...
by susuguo | Nov 21, 2022
By Casey B. Mulligan and Tomas J. Philipson President Biden has accused Republicans of scheming to cut Medicare. In fact it is his signature legislation, the Inflation Reduction Act, that will lead to benefit cuts and premium increases for seniors. Medicare’s popular...
by susuguo | Jul 11, 2022
By Joe Grogan and Casey B. Mulligan Washington is a town not known for bipartisan agreement. But its swarms of drug-company lobbyists appear to have united both parties in opposition to pharmacy benefit managers. PBMs are taking the blame for high drug prices. PBMs...
by susuguo | Jun 28, 2022
By Tomas J. Philipson There’s an economic explanation for America’s obesity problem. High-calorie foods are cheaper than ever, and changes in the way we work have created a sedentary nation. Happily, the market is generating a solution: medical innovations that can...
